New clue to the cause of Alzheimer's
(getting older and older)
Please Help Support Alzheimer's Research Today!
Your Alzheimer's donation will help billions live without it.
The proteins, which carry specific sugar molecules, are found in greater concentrations in patients with dementia caused by Alzheimer’s disease than in patients with dementia caused by other diseases. This gives hope for new forms of treatment in the future. Göran Larson is a professor at the Sahlgrenska Academy and one of the authors of the article published in the revered journal Proceedings of the National Academy of Sciences USA (PNAS).
“When it comes to the link to Alzheimer’s, we’re thinking first and foremost of the possibilities to use these molecules as markers for an early and reliable diagnosis, but also, of course, of what role these molecules may play in the development and course of the disease.”
These new molecules give researchers another way of thinking of the mechanisms behind Alzheimer’s disease. Larson and his research team are already working with other researchers at the Sahlgrenska Academy and Chalmers University of Technology to develop new analytical techniques for measuring the concentrations of these molecules in cerebrospinal fluid. The aim is to try to make the analyses more sensitive, as well as simpler, cheaper and more accessible so that they can be used as routine clinical assays when investigating dementia. Continue to read: innovations-report.com
“When it comes to the link to Alzheimer’s, we’re thinking first and foremost of the possibilities to use these molecules as markers for an early and reliable diagnosis, but also, of course, of what role these molecules may play in the development and course of the disease.”
These new molecules give researchers another way of thinking of the mechanisms behind Alzheimer’s disease. Larson and his research team are already working with other researchers at the Sahlgrenska Academy and Chalmers University of Technology to develop new analytical techniques for measuring the concentrations of these molecules in cerebrospinal fluid. The aim is to try to make the analyses more sensitive, as well as simpler, cheaper and more accessible so that they can be used as routine clinical assays when investigating dementia. Continue to read: innovations-report.com
